Novo Nordisk stock news
On September 21, 2026, Novo Nordisk announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for CagriSema, a once--weekly fixed--dose combination of cagrilintide and semaglutide, for chronic weight management. The filing is supported by data from the REDEFINE clinical trial program, which demonstrated superior weight loss efficacy compared to semaglutide alone. This regulatory milestone marks a critical step in the company's strategy to maintain its leadership in the obesity market and address intensifying competition from next--generation incretin therapies. The FDA is expected to complete its review and issue a decision by mid--2027.